share_log

Novavax | 144: Notice of proposed sale of securities pursuant to Rule 144

Novavax | 144: Notice of proposed sale of securities pursuant to Rule 144

诺瓦瓦克斯医药 | 144：拟议出售证券
美股SEC公告 ·  2024/12/14 01:16

Moomoo AI 已提取核心信息

Rachel K. King, a Board Member of Novavax, plans to sell 4,150 shares of Common A stock on 12/13/2024. The aggregate market value of the shares to be sold is $37,350. This transaction involves securities acquired through different means.Of the shares to be sold, 700 were acquired through a market purchase on 05/19/2024, with cash payment made through a brokerage account. The remaining 3,450 shares were obtained on 06/25/2021 through an RSU redemption, as part of employment compensation from Novavax.The company's records indicate no securities were sold by the insider during the past three months prior to this announcement. The official notice for this planned transaction was filed on 12/13/2024, coinciding with the proposed sale date.
Rachel K. King, a Board Member of Novavax, plans to sell 4,150 shares of Common A stock on 12/13/2024. The aggregate market value of the shares to be sold is $37,350. This transaction involves securities acquired through different means.Of the shares to be sold, 700 were acquired through a market purchase on 05/19/2024, with cash payment made through a brokerage account. The remaining 3,450 shares were obtained on 06/25/2021 through an RSU redemption, as part of employment compensation from Novavax.The company's records indicate no securities were sold by the insider during the past three months prior to this announcement. The official notice for this planned transaction was filed on 12/13/2024, coinciding with the proposed sale date.
Rachel K. King，诺瓦瓦克斯医药的董事会成员，计划在2024年12月13日卖出4,150股普通A股。将要出售的股票总市场价值为37,350美元。此次交易涉及通过不同方式获得的证券。在待售的股票中，700股是通过在2024年05月19日的市场购买获得的，现金支付通过券商账户完成。其余的3,450股是在2021年06月25日通过RSU赎回获得的，作为诺瓦瓦克斯医药的就业补偿。公司的记录显示，在本公告前的三个月内，内部人士没有出售任何证券。该计划交易的正式通知于2024年12月13日提交，与拟议的销售日期一致。
Rachel K. King，诺瓦瓦克斯医药的董事会成员，计划在2024年12月13日卖出4,150股普通A股。将要出售的股票总市场价值为37,350美元。此次交易涉及通过不同方式获得的证券。在待售的股票中，700股是通过在2024年05月19日的市场购买获得的，现金支付通过券商账户完成。其余的3,450股是在2021年06月25日通过RSU赎回获得的，作为诺瓦瓦克斯医药的就业补偿。公司的记录显示，在本公告前的三个月内，内部人士没有出售任何证券。该计划交易的正式通知于2024年12月13日提交，与拟议的销售日期一致。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Dogwood Therapeutics
    DWTX
    -- 15.265
    Transcode Therapeutics
    RNAZ
    -- 7.220
    Hepion Pharmaceuticals
    HEPA
    -- 0.2191
    Nutriband
    NTRB
    -- 10.020
    Alaunos Therapeutics
    TCRT
    -- 2.2193
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    中美谈话新契机，通胀不再？
    🎙️讨论： 1. 你认为特朗普上台后，对华政策将如何影响中国资产？ 2. 美股市场通胀风险下降，有哪些利好板块？ 展开
    中国将在未来一年采取"适度宽松"的货币政策，这是自2011年以来的首次转向宽松。